You are here: Industry Insights > Seqirus

News List

Glenmark Announces Licensing Agreement with Seqirus americanpharmaceuticalreview
July 11, 2018
Glenmark Pharmaceuticals announced its subsidiary Glenmark Specialty has entered into an exclusive licensing agreement with Seqirus to commercialize Ryaltris in Australia and New Zealand.
Seqirus announces £40m UK fill-and-finish flu vaccine facility pharmafile
November 10, 2017
Seqirus, a flu vaccine specialist unit of CSL, a global biotechnology company, has announced that it will invest £ 40 million at its Liverpool, England, facility into a new reprocessing facility
Seqirus’ adjuvanted quadrivalent flu vaccine shows better protection for young children fiercepharma
September 13, 2017
Seqirus already has the first and only FDA-approved cell-based flu vaccine, Flucelvax, for people four years and older.
News of Note—Seqirus, VBI and Altimmune fiercepharma
August 23, 2017
Approval of Fluad in the U.K. is among this week's news of note.
News of Note—Seqirus, Fujifilm and more fiercepharma
August 17, 2017
A Fujifilm Diosynth partnership and flu vaccine effectiveness are among this week's news of note.
Seqirus Announces Advancement in Cell-Based Influenza Vaccine Technology americanpharmaceuticalreview
June 22, 2017
Seqirus announced an advancement in the use of cell-based technology at its manufacturing facility in North Carolina.

Previous page 1 2 Next page